1 completed, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Pemetrexed 500 mg: new trials by email Literature Review of Pemetrexed 500 mg trials Research Report on Pemetrexed 500 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations Amivantamab, Lazertinib, Pemetrexed 500 mg - Metastatic Non-small Cell Lung Cancers | Phase 2 | Completed | Latin American Cooperative Oncology Group | 54 | 2023-05-24 | 2026-08-28 |
| Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed 500 MG, Erlotinib - Biliary Tract Cancer | Phase 2 | Unknown | Samsung Medical Center | 44 | 2021-07-09 | 2022-06-15 |
Latin American Cooperative Oncology Group (1) · Samsung Medical Center (1)
Brazil (1) · South Korea (1)